Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

TORONTO, ONTARIO – January 26, 2022 – Magen Ventures I Inc. (TSXV: MAGN.P) (“Magen” or the “Company”) and Grey Wolf Animal Health Inc. (“Grey Wolf” or the “Target”) are pleased to announce that they have entered into a non-binding letter of intent dated January 26, 2022 (the “LOI”), pursuant to which Magen and Grey Wolf intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of Magen (the “Transaction”). It is intended that the Transaction will be an arm’s length “Qualifying Transaction” for Magen, as such term is defined in Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange (the “TSXV”).